FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4387406045> ?p ?o ?g. }

• W4387406045 abstract "Abstract Disclosure: F.J. Lopez Maldonado: None. R.A. Cota: None. Case presentation: A 41-year-old male patient with family history of T2DM in both parents and brother, personal history of mild alcohol consumption and a sedentary job (public accountant), and obesity since age 30 presented to the endocrinology clinic due to failure to lose weight after 1 year of treatment with a nutritionist. During his first visit, the was asymptomatic and had acanthosis nigricans, his blood pressure was measured at 142/92 mmHg, weight was 100.8 kg, waist circumference was 128 cm, and serum glucose was at 280 mg/dL with an HbA1c of 11.9%. Further laboratory tests showed elevated levels of triglycerides (310 mg/dL), LDL (139 mg/dL), AST (96 U/L), and ALT (65 U/L). Two days later, glucose and HbA1c were repeated with similar results. A liver ultrasound was ordered which revealed diffuse hyperechogenicity of the liver and severe fatty liver disease. The ASCVD risk score was 5.4%. The patient was diagnosed with T2DM, obesity, mixed dyslipidemia, and fatty liver disease. The patient received education, nutrition support, exercise, and pharmacotherapy management with stepped-dose oral semaglutide without metformin. The dose was increased monthly starting at 3 mg and reaching the target dose of 14 mg QD. After three months, the patient demonstrated significant improvements in various parameters such as blood pressure (−10/−8 mmHg), weight (−9.8 kg), waist circumference (−25 cm), serum glucose (−179 mg/dL), HbA1C (−5.7%), triglycerides (−154 mg/dL), LDL (−18 mg/dL), AST (−60 U/L), and ALT (−38 U/L), along with an increase in HDL (+6 mg/dL). After approximately 4 months on the target dose the patient showed further improvements in several parameters including ASCVD risk score (2.1%), blood pressure (−20/12 mmHg), weight (−14.8 kg), waist circumference (−30 cm), serum glucose (−183 mg/dL), HbA1C (−6%), LDL (−25 mg/dL), AST (−63 U/L), and ALT (−40 U/L), and HDL (+10 mg/dL), except for triglyceride levels (−130 mg/dL). Follow-up liver ultrasound showed significant improvement in fatty liver disease. Real-world experiences with newly introduced drugs should be reported, as they may have beneficial effects beyond the ones studied. Oral semaglutide, the first oral GLP-1 analog, has been shown to be non-inferior to other subcutaneous GLP-1 analogs. In this case, improvements were observed in glycemic control, weight loss, lipid levels, and a reduction in cardiovascular risk, as well as an improvement in fatty liver disease. Presentation: Friday, June 16, 2023" @default.
• W4387406045 created "2023-10-07" @default.
• W4387406045 creator A5050249722 @default.
• W4387406045 creator A5093017846 @default.
• W4387406045 date "2023-10-01" @default.
• W4387406045 modified "2023-10-08" @default.
• W4387406045 title "FRI652 Type 2 Diabetes Management: More GLP1 Agonists And Less Metformin?" @default.
• W4387406045 doi "https://doi.org/10.1210/jendso/bvad114.871" @default.
• W4387406045 hasPublicationYear "2023" @default.
• W4387406045 type Work @default.
• W4387406045 citedByCount "0" @default.
• W4387406045 crossrefType "journal-article" @default.
• W4387406045 hasAuthorship W4387406045A5050249722 @default.
• W4387406045 hasAuthorship W4387406045A5093017846 @default.
• W4387406045 hasBestOaLocation W43874060451 @default.
• W4387406045 hasConcept C126322002 @default.
• W4387406045 hasConcept C134018914 @default.
• W4387406045 hasConcept C2776193436 @default.
• W4387406045 hasConcept C2777180221 @default.
• W4387406045 hasConcept C2778096610 @default.
• W4387406045 hasConcept C2778772119 @default.
• W4387406045 hasConcept C2779134260 @default.
• W4387406045 hasConcept C2780323712 @default.
• W4387406045 hasConcept C2781179581 @default.
• W4387406045 hasConcept C511355011 @default.
• W4387406045 hasConcept C555293320 @default.
• W4387406045 hasConcept C71924100 @default.
• W4387406045 hasConcept C84393581 @default.
• W4387406045 hasConcept C90924648 @default.
• W4387406045 hasConceptScore W4387406045C126322002 @default.
• W4387406045 hasConceptScore W4387406045C134018914 @default.
• W4387406045 hasConceptScore W4387406045C2776193436 @default.
• W4387406045 hasConceptScore W4387406045C2777180221 @default.
• W4387406045 hasConceptScore W4387406045C2778096610 @default.
• W4387406045 hasConceptScore W4387406045C2778772119 @default.
• W4387406045 hasConceptScore W4387406045C2779134260 @default.
• W4387406045 hasConceptScore W4387406045C2780323712 @default.
• W4387406045 hasConceptScore W4387406045C2781179581 @default.
• W4387406045 hasConceptScore W4387406045C511355011 @default.
• W4387406045 hasConceptScore W4387406045C555293320 @default.
• W4387406045 hasConceptScore W4387406045C71924100 @default.
• W4387406045 hasConceptScore W4387406045C84393581 @default.
• W4387406045 hasConceptScore W4387406045C90924648 @default.
• W4387406045 hasIssue "Supplement_1" @default.
• W4387406045 hasLocation W43874060451 @default.
• W4387406045 hasOpenAccess W4387406045 @default.
• W4387406045 hasPrimaryLocation W43874060451 @default.
• W4387406045 hasRelatedWork W2018645250 @default.
• W4387406045 hasRelatedWork W2039412011 @default.
• W4387406045 hasRelatedWork W2105403615 @default.
• W4387406045 hasRelatedWork W2350706782 @default.
• W4387406045 hasRelatedWork W2393378262 @default.
• W4387406045 hasRelatedWork W2520648843 @default.
• W4387406045 hasRelatedWork W2904715359 @default.
• W4387406045 hasRelatedWork W2987751125 @default.
• W4387406045 hasRelatedWork W4380836775 @default.
• W4387406045 hasRelatedWork W1920632900 @default.
• W4387406045 hasVolume "7" @default.
• W4387406045 isParatext "false" @default.
• W4387406045 isRetracted "false" @default.
• W4387406045 workType "article" @default.